Histone Deacetylase Inhibitors Market Outlook:
Histone Deacetylase Inhibitors Market size was valued at USD 1.43 billion in 2025 and is expected to reach USD 2.97 billion by 2035, expanding at around 7.6% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of histone deacetylase inhibitors is evaluated at USD 1.53 billion.
The reason behind the growth in the market is impelled by the rising cases of cancer across the globe. HDAC inhibitors that allow acetylation equilibrium to be restored are clinically proven to be helpful in oncology, particularly for hematological cancers, as a single agent or in combination therapies. Worldwide, the age-standardized incidence rates of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in males & females are projected to reach 1.2 & 1.0 per 100,000 and 7.3 & 4.9 per 100,000 by 2044, respectively (ScienceDirect). Similarly, a 2024 journal from the ASH publications predicted the number of new leukemia cases in the world to be 519,540 by 2050.
This demography indicates the heightening demand for innovative targeted therapies, including histone deacetylase (HDAC) inhibitors. The economic burden on associated patients is significantly rising, particularly in high-income countries, which is pushing companies and academia to produce therapeutics with value-based payers’ pricing. On this note, a study on healthcare expenses on hematologic malignancy treatments in the U.S. was published by the ASH Publication in March 2024. It concluded the all-cause median cost per patient to be USD 3,31,827.0 during an allogeneic transplant procedure. Thus, the market is currently dedicated to offering affordable alternatives to conventional expensive therapies.
